Psychedelic based treatment for Parkinson’s disease and other psychiatric disorders

Unmet Need: Non-hallucinogenic psychedelic treatment for neurological psychiatric disorders

Current treatments for psychiatric and neurological disorders are not effective. Psychedelic drugs have shown great potential to improve certain brain disorders, however unwanted hallucinogenic side effects have deterred their adoption. Addressing this issue is crucial to provide patients with effective treatment options with minimal side effects for conditions like Parkinson's disease (PD) and dementia.

The Technology: Pharmacological treatment for brain disorders using a non-hallucinogenic serotonin 2A agonist

This technology identifies a role for Ariadne, a partial serotonin 2A receptor agonist and a psychedelic analogue, as a therapeutic treatment for Parkinson’s disease. Remarkably, Ariadne shows no hallucinogenic effects and efficiently targets PD symptoms in a mouse model. This drug proposes a safer and more efficacious treatment for a variety of neurological and psychiatric disorders involving serotonin 2A receptors.

This technology has been validated in vivo in mice.

Applications:

Treatment for neurodegenerative diseases (Parkinson’s disease and dementia)
Treatment for drug addiction
Treatment for psychiatric disorders: depression, anxiety, schizophrenia, bipolar disorder
Research tool for studying the 5-HT_2A receptor

Advantages:

Non-hallucinogenic
Broad therapeutic potential

Lead Inventor:

Dalibor Sames, Ph.D.

Patent Information:

Patent Pending

Related Publications:

Cunningham MJ, Bock HA, Serrano IC, Bechand B, Vidyadhara DJ, Bonniwell EM, Lankri D, Duggan P, Nazarova AL, Cao AB, Calkins MM, Khirsariya P, Hwu C, Katritch V, Chandra SS, McCorvy JD, Sames D. “Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs” ACS Chem Neurosci. 2023 Jan 4; 14(1): pp. 119-135

Tech Ventures Reference:

IR CU21182, CU21360, CU23079
Licensing Contact: Beth Kauderer